Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01025193 · ClinicalTrials.gov registry record · Phase 2
Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant
A Phase 2 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01025193: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT01025193 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01025193, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
If subjects are listed for kidney transplant and are considered sensitized, this means they have a high amount of antibodies in their blood that could react to a kidney transplant offered for them. Antibodies are protein substances made by the body that fight anything that the body considers as a threat to it, such as infection or a kidney transplant. Sensitization may be due to prior transplants, pregnancy, or blood transfusions. Being sensitized can increase the subject's kidney transplant waiting time as it is more difficult to find a suitable kidney transplant for them that their antibodies will not react to. The purpose of this research study is to see if giving the investigational drug belimumab up to one year pre-transplant can de-sensitize the subjects, or decrease the amount of antibodies in their blood. This may help make the subjects eligible to receive a kidney transplant more quickly. If after receiving belimumab, the subjects are compatible with a donor kidney offered and are medically suitable for transplant at that time, a kidney transplant will be performed.
Interventions
- DRUG Belimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01025193
The ClinicalTrials.gov registry entry for NCT01025193 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belimumab is the first listed.
NCT01025193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01025193 about?
NCT01025193 is a clinical study titled "Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant". If subjects are listed for kidney transplant and are considered sensitized, this means they have a high amount of antibodies in their blood that could react to a kidney transplant offered for them. Antibodies are protein substances made by the body that fight anything that the body considers as a th...
What is the current status of trial NCT01025193?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2010-02. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01025193?
The interventions under investigation include: Belimumab (DRUG).
Who is sponsoring clinical trial NCT01025193?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.